LifeSignals' UbiqVue 2A System Receives FDA Clearance for Continuous Wireless Patient Monitoring
Key Insights
LifeSignals (search)' UbiqVue 2A system, featuring a wearable biosensor, has gained FDA 510(k) clearance for continuous remote patient monitoring in diverse settings.
The biosensor, worn on the chest, monitors 13 physiological parameters, including SpO2 (search), ECG, respiration rate, and body temperature, transmitting data securely to a cloud-based system.
The UbiqVue system aims to replace manual spot-checking with continuous, near real-time monitoring, enhancing patient safety and streamlining healthcare professional workflows.
LifeSignals (search) Inc. has announced that its UbiqVue 2A Multiparameter System has received FDA 510(k) clearance. This clearance marks a significant advancement in continuous wireless patient monitoring, enabling its use across various healthcare settings, including hospitals, remote locations, and at-home care. The system is designed to enhance patient safety through continuous monitoring of physiological data, replacing traditional spot-checks that can be time-consuming and less accurate.
The UbiqVue 2A system centers around a single-use wearable biosensor placed on the chest. This biosensor continuously collects and transmits data on 13 physiological parameters. These parameters include SpO2 (search) levels, 2-channel ECG, pulse rate, photoplethysmography (PPG), respiration rate, body temperature, and motion. The device uses white light spectral SpO2 technology, licensed from BioIntelliSense (search), to ensure accurate SpO2 monitoring across diverse skin tones.
Key Features and Benefits
Data collected by the UbiqVue 2A biosensor is encrypted and transmitted in near real-time via a relay app or access point to a secure, cloud-based system. Healthcare professionals can access this data through the UbiqVue web portal and receive alert notifications, facilitating timely intervention and improved patient care. The system is designed for seamless integration into existing clinical workflows and is scalable to accommodate large patient populations.
Surendar Magar, Co-founder and CEO of LifeSignals (search), stated that this FDA clearance is a major milestone in the company's mission to deliver bedside patient monitor-like functionality via an affordable, single-use biosensor. He also noted the company's commitment to expanding the UbiqVue system with additional vital signs and advanced AI capabilities, with the goal of transforming healthcare at scale through global partnerships.
Engineering and Regulatory Achievements
Thomas Varghese, Chief Engineering Officer at LifeSignals (search), highlighted the engineering innovation required to develop the UbiqVue system, from silicon design and wireless coexistence to the collection of multiple vital signs from the chest. Saravanan Balasubramanian, VP of Medical Technology & Regulatory Operations, emphasized the company's commitment to delivering scalable solutions, addressing SpO2 (search) accuracy across diverse skin tones, ensuring data security, maintaining wireless reliability, and meeting latency requirements for timely alert generation.
Impact on Patient Care and Population Health
The UbiqVue system is poised to reshape individual patient care and population health strategies. By providing continuous, real-time data on key physiological parameters, the system enables healthcare providers to proactively manage patient health, potentially reducing hospital readmissions and improving overall outcomes. LifeSignals (search) aims to continue innovating wireless solutions for healthcare systems globally, reinforcing its commitment to improving patient care through advanced technology.